MERZ
31.1.2020 09:04:13 CET | Business Wire | Press release
Merz, a global leader in medical aesthetics, announced today that data on the Merz Aesthetics product portfolio, including Belotero® , Cellfina® and Radiesse® will be featured in oral and poster presentations at the 2020 International Master Course on Aging Science (IMCAS) World Congress, to be held from 30 January to 1 February 2020 in Paris, France.
“This meeting provides a platform for Merz Aesthetics to not only foster education and continuous training but also, to engage in thoughtful industry conversations while connecting with medical aesthetics physicians and fellow industry leaders from around the world,” said Bob Rhatigan, CEO of Merz Aesthetics. “We are grateful that our heritage and innovation in this space allows us to partner with world-renowned medical aesthetic experts, to share research on the diversified Merz Aesthetics product portfolio at the IMCAS World Congress.”
In addition to the poster presentations listed below, Merz Aesthetics is sponsoring the symposium event “Facial Rejuvenation: Interactive Sessions to Level-Up Your Injection Skills”, to be held on Saturday, 1 February at 10.30h – 12.30h, Room Amphi Bleu . The session will be opened by Bob Rhatigan, CEO of Merz Aesthetics and will include treatment insights from four international expert speakers:
- Dr. Tatjana Pavicic – Dermatologist, Germany
- Dr. Kate Goldie – Aesthetic Physician, United Kingdom
- Prof. Yana Yutskovskaya – Dermatologist, Russia
- Dr. Jani van Loghem – Aesthetic Physician, Netherlands
Oral Presentations
Independent presentations including data on the Merz Aesthetics portfolio:
What’s new in minimally invasive treatments
- Update on dermal fillers (99921) – Kate Goldie, MBChB – UK. Thursday, 30 January, 17.54 – 18.06h, Amphi Bleu – Level 2
Body shaping and cellulite
- Cellulite and skin laxity (93276). Doris Hexsel, Dermatologist – Brazil. Thursday, 30 January, 10.30 – 10.42h, Amphi Bleu – Level 2
- Cellulite treatment update: how dimples, laxity and volume can be effectively treated (98147)1 . Gabriela Casabona, MD– Spain. Thursday, 30 January, 11.18 – 11.30h, Amphi Bleu – Level 2
Biostimulatory fillers
- Biostimulators: how dilution/diffusion interferes with outcome (93391). Gabriela Casabona, MD – Spain. Saturday, 1 February, 16.30 – 16.42, Room 143 - Level 1
E-Poster Presentations
E-Posters will be available for viewing at the Poster Zone on Level 2 , from Thursday, 30 January to Saturday, 1 February 2020 .
- Distribution of cohesive polydensified matrix cross-linked hyaluronic acid volumizing gel in ex vivo human skin model. Christina Wollenburg, Jeanette Simon, Dr. Kay Marquardt, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
- Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness. Gabriela Casabona, MD – Spain. Dr. Bartosch Nowag, Daniela Schäfer, Davide Greco, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
BOCOUTURE® Milestone
This year, Merz is also celebrating the ten-year anniversary of BOCOUTURE® (incobotulinumtoxin A) in Europe. The botulinum toxin is part of the Merz Aesthetics portfolio and has received approval in 15 countries in Europe within the last ten years. A Booth Talk about “BOCOUTURE® - 10 Years of a Unique Neurotoxin” with Dr. Thomas Rappl will take place Friday, 31 January, 16.00, Booth N° P251 .
Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KgaA.
About Merz
Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,213 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com .
1 Merz supported Investigator Initiated Trials
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005133/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 15:36:00 CEST | Press release
David Ogg appointed Vice Chairman and Brian Andreyko named CEO MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going o
Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 15:00:00 CEST | Press release
The Company recently completed an additional $5.0 million of common stock repurchases and $5.0 million of debt prepayment that brings total fiscal year-to-date capital return and balance sheet optimization to $30.9 million Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction TransactionsDebt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom